Evidence map›Paper›PMID 39770777›Full record

ArticleMicroorganisms2024

The Clinical Anatomy of SARS-CoV-2 Variants of Concern in Central Greece During October 2020-July 2022.

Ioanna Voulgaridi, Zacharoula Bogogiannidou, Katerina Dadouli, Achilleas P Galanopoulos, Maria A Kyritsi, Alexandros Vontas, Alexia Matziri, Konstantina Kola, Evangelia Vachtsioli, Lemonia Anagnostopoulos and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ioanna VoulgaridiLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.ORCID 0000-0002-7352-0934
Zacharoula BogogiannidouLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Katerina DadouliLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.ORCID 0000-0002-8821-0795
Achilleas P GalanopoulosLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Maria A KyritsiLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.ORCID 0000-0002-4689-4623
Alexandros VontasLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.ORCID 0000-0001-5424-0235
Alexia MatziriLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Konstantina KolaLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Evangelia VachtsioliLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Lemonia AnagnostopoulosLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Anastasia TsisparaEmergency Department, General Hospital of Larissa, 413 34 Larissa, Greece.
Katerina G OikonomouIntensive Care Unit, General Hospital of Larissa, 413 34 Larissa, Greece.
Dimitris BabalisEmergency Department, General Hospital of Larissa, 413 34 Larissa, Greece.
Efthymia PetinakiDepartment of Microbiology, University Hospital of Larissa, University of Thessaly, 413 34 Larissa, Greece.
Maria TseroniDepartment of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, 157 72 Athens, Greece.ORCID 0000-0003-1463-7056
Fani KalalaDepartment of Immunology and Histocompatibility, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.ORCID 0009-0001-5588-8014
Matthaios SpeletasDepartment of Immunology and Histocompatibility, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Varvara A MouchtouriLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.
Christos HadjichristodoulouLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 413 34 Larissa, Greece.ORCID 0000-0002-4769-8376

Funding

Pfizer- Hellas S.A 61304
6 · The paper itself

Abstract

The emergence of SARS-CoV-2 variants of concern (VOCs) during the COVID-19 pandemic necessitates investigation into their clinical differentiation and outcomes. This study aimed to examine these differences among VOCs, considering multiple related factors. An observational cohort study was conducted on patients diagnosed with SARS-CoV-2 infection via nasopharyngeal/oropharyngeal swab who visited the emergency department of a public Greek hospital between October 2020 and July 2022 during different VOC circulation in the region. Data on clinical manifestations, outcomes, and medical history (comorbidities, prior SARS-CoV-2 infection, vaccination status against COVID-19) were collected through a questionnaire and medical records for those hospitalized. A total of 913 patients were included in this study (813 adults ≥18 years old, 100 children <18 years old). Significant differences were observed across VOCs for both adults and children. A lower proportion of children developed symptoms during the non-Omicron variants, 73.5%, compared to Omicron variants, 86.4%. Fever, dyspnea, and taste and smell disorders were observed more frequently among non-Omicron adult cases, in contrast to upper respiratory symptoms, which were more common symptoms among Omicron infections. The non-Omicron variants were associated with higher rates of hospitalization at 30.6%, pneumonia at 23.0%, and death at 6.1% compared to Omicron variants at 8.0%, 5.0%, and 1.8%, respectively. Vaccination against COVID-19 was shown to be a protective factor for severe outcomes. Our findings suggest distinct clinical presentations and outcomes associated with different VOCs. Despite the fact that current VOCs circulating are less severe, the COVID-19 vaccine continues to play a protective role for severe cases.

Indexed as

differences in severitydifferences in symptomatologyoutcomes of COVID-19SARS-CoV-2vaccinationvariants of concern (VOCs)

Identifiers

PMID39770777
PMCPMC11678192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.